AcelRx Pharmaceuticals, Inc. (ACRX)
-NasdaqGM | Prev Close: | 9.60 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 13.00 |
|---|
| Beta: | 1.79 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 2.27 - 10.59 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 432,620 |
|---|
| Market Cap: | 357.48M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.47 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 5 of Last Week's Biggest Winnersat Motley Fool(Sun, Jun 2)
- 4 Top Small Cap Biotech Acquisition Targetsat Seeking Alpha(Fri, May 31)
- Imprimis' Platform Set To Bring Library Drug Formulations Quickly To Marketat Seeking Alpha(Thu, May 30)
- Wednesday 5/29 Insider Buying Report: ACRX, CSVat Forbes(Wed, May 29)
- AcelRx Pharmaceuticals to Present at the Jefferies 2013 Global HealthcarePR Newswire(Wed, May 29)
- 5 of Last Week's Biggest Winnersat Motley Fool(Sun, May 26)
- This Week in Biotechat Motley Fool(Sat, May 25)
- 4 Healthcare Stock Stories For Tuesday Investment Wellnessat Wall St. Cheat Sheet(Tue, May 21)
- Why AcelRx Pharmaceuticals Shares Spiked Temporarilyat Motley Fool(Tue, May 21)
- AcelRx pain treatment meets late-stage study goalsAP(Tue, May 21)
- Home Deport gains on strong resultsoptionMONSTER(Tue, May 21)
- AcelRx announces positive results from Phase 3 study of Sufentanil PCA systemat theflyonthewall.com(Tue, May 21)
- Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative PainPR Newswire(Tue, May 21)
- AcelRx Pharmaceuticals to Present at the UBS Global Healthcare ConferencePR Newswire(Thu, May 16)
- ACELRX PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Tue, May 14)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 118.96 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.96 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.22 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain.
View More 
0.91%